PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.
P/B ratio for PolarityTE, Inc. (PTE)
P/B ratio as of 2022: 0.27
According to PolarityTE, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.27. At the end of 2021 the company had a P/B ratio of 2.44.
P/B ratio history for PolarityTE, Inc. from 1999 to 2022
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2022 | 0.27 |
| 2021 | 2.44 |
| 2020 | 0.96 |
| 2019 | 1.67 |
| 2018 | 2.85 |
| 2017 | 27.04 |
| 2016 | 1.39 |
| 2015 | 0.59 |
| 2014 | 1.55 |
| 2013 | 1.27 |
| 2012 | 1.36 |
| 2011 | 5.59 |
| 2010 | 47.60 |
| 2009 | 30.23 |
| 2008 | 43.38 |
| 2007 | 19.50 |
| 2006 | 23.82 |
| 2005 | 7.34 |
| 2004 | 8.73 |
| 2003 | -1.22 |
| 2002 | -7.29 |
| 2001 | -129.88 |
| 2000 | 3.71 |
| 1999 | 4.84 |